To further elucidate the molecular mechanisms underlying the effects of febuxostat against MASLD, additional WB analysis (Figure 7) revealed that the hepatic phosphorylated c-Jun N-terminal kinase (p-JNK) protein expression ratio was notably decreased in the HF + F group relative to the HF group (p < 0.05). This evidence concerns the gene MAPK8 and metabolic dysfunction-associated steatotic liver disease.